EYEPOINT PHARMACEUTICALS INC
EYEPOINT PHARMACEUTICALS INC logo
EYPT

EYEPOINT PHARMACEUTICALS INC (EYPT)

$4.563.59%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$4.55
Day's Range
$4.83
$2.19
52-Week Range
$14.41
1 month return24.93%
3 month return15.56%
1 year return51.33%
5 year return300.0%

Analyst Recommendation

based on 12 analysts ratings

Buy
91%
Buy
8%
Hold
0%
Sell

Based on 12 Wall street analysts offering stock ratings for EYEPOINT PHARMACEUTICALS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 608.99%

Current

$4.56

Target

$32.33

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
11
5
11
Hold
1
0
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization161.2M
Book Value$4.0
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-2.1
Wall Street Target Price32.33

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)0.73
Enterprise Value-11620663
Enterprise Value/Revenue0.11
Enterprise Value/Ebitda0.16

Technicals

Beta0.91
50 Day MA3.51
200 Day MA7.43

Institutional Holdings

Franklin Resources Inc

16.46%

Essex Woodlands Health Ventures

12.3%

RA Capital Management, LLC

9.89%

Suvretta Capital Management, LLC

9.49%

Adage Capital Partners Gp LLC

5.72%

BlackRock Inc

4.84%

Company Information

EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.
OrganizationEYEPOINT PHARMACEUTICALS INC
Employees122
CEOMs. Nancy S. Lurker
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is EYEPOINT PHARMACEUTICALS INC share price today?

Can Indians buy EYEPOINT PHARMACEUTICALS INC shares?

How can I buy EYEPOINT PHARMACEUTICALS INC shares from India?

Can Fractional shares of EYEPOINT PHARMACEUTICALS INC be purchased?

What are the documents required to start investing in EYEPOINT PHARMACEUTICALS INC stocks?

What are today’s High and Low prices of EYEPOINT PHARMACEUTICALS INC?

What are today’s traded volumes of EYEPOINT PHARMACEUTICALS INC?

What is today’s market capitalisation of EYEPOINT PHARMACEUTICALS INC?

What is the 52 Week High and Low Range of EYEPOINT PHARMACEUTICALS INC?

How much percentage EYEPOINT PHARMACEUTICALS INC is down from its 52 Week High?

How much percentage EYEPOINT PHARMACEUTICALS INC is up from its 52 Week low?

What are the historical returns of EYEPOINT PHARMACEUTICALS INC?

Who is the Chief Executive Officer (CEO) of EYEPOINT PHARMACEUTICALS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*